Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29767252 | 1.00 | SCN2A (0.59) | SCN2AALDH1A1PKMMEN1MAPT | |
| SCHEMBL30758087 | 0.85 | ALDH1A1 (0.48) | SCN2AALDH1A1PKMMEN1MAPT | |
| SCHEMBL13997433 | 0.79 | HTR3E (0.51) | SCN2AALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL20201233 | 0.79 | KDM4E (0.43) | SCN2AALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL11039827 | 0.76 | KDM4E (0.43) | SCN2AALDH1A1MAPTKDM4EGAA | |
| SCHEMBL11826455 | 0.75 | ALDH1A1 (0.56) | ALDH1A1PKMMAPTTHRBKDM4E | |
| SCHEMBL13082241 | 0.74 | ALDH1A1 (0.60) | ALDH1A1PKMMEN1MAPTTHRB | |
| SCHEMBL28034018 | 0.74 | ERN1 (0.53) | SCN2AALDH1A1MAPTKDM4EGAA | |
| SCHEMBL27860088 | 0.73 | SCN2A (0.44) | SCN2AALDH1A1MEN1MAPTTHRB | |
| SCHEMBL20550647 | 0.73 | SCN2A (0.54) | SCN2AALDH1A1MEN1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226342-A1 | REACTIVE OXYGEN SPECIES IMAGING AGENTS | WASHINGTON UNIVERSITY (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2021147699-A1 | PYRIDOHETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-07-29 | — | — | WO | disclosed |
| US-10973819-B2 | Small molecules inhibitors of RAD51 | THE UNIVERSITY OF CHICAGO (US) | 2021-04-13 | — | — | US | disclosed |
| US-10973819-B2 | Small molecules inhibitors of RAD51 | THE UNIVERSITY OF CHICAGO (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190083491-A1 | SMALL MOLECULES INHIBITORS OF RAD51 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-21 | — | — | US | disclosed |
| US-20190083491-A1 | SMALL MOLECULES INHIBITORS OF RAD51 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-21 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-22 | — | — | US | disclosed |
| US-8071597-B2 | Pyrazine compounds and uses as PI3K inhibitors | MERCK SERONO SA (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-3939159-A | ANTICONVULSANT, CNS DEPRESSANT | AMERICAN HOECHST CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226342-A1 | REACTIVE OXYGEN SPECIES IMAGING AGENTS | ROS1, NOX4, CYBB | SCN2A 3909/4885ALDH1A1 1044/4885PKM 1646/4885 |
| US-20190083491-A1 | SMALL MOLECULES INHIBITORS OF RAD51 | RAD51, MRE11, DDB1 | SCN2A 3741/4885ALDH1A1 4305/4885PKM 4070/4885 |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | SCN2A 2283/4885ALDH1A1 3396/4885PKM 823/4885 |
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | SCN2A 2975/4885ALDH1A1 97/4885PKM 2660/4885 |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | SCN2A 2369/4885ALDH1A1 2357/4885PKM 871/4885 |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | SCN2A 2369/4885ALDH1A1 2357/4885PKM 871/4885 |
| US-10973819-B2 | Small molecules inhibitors of RAD51 | RAD51, MRE11, DDB1 | SCN2A 3741/4885ALDH1A1 4305/4885PKM 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.